title: Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells.
abstract: The chromosomal aberrations underlying the development of resistance to fluoropyrimidines have not yet been identified. To characterise the genomic changes that induce the development of resistance to fluoropyrimidines, we used comparative genomic hybridisation (CGH) to analyse and compare the parent DLD-1 human colorectal cancer cell line and two cell lines, DLD-1/5-FU and DLD-1/FdUrd, which were resistant to 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd), respectively. Both resistant cell lines showed a genetic aberration derived from the parental cell line DLD-1. Losses of 3p and 3q were also detected as additional genetic changes in the two resistant cell lines. Both resistant cell lines showed decreased orotate phosphoribosyltransferase (OPRT) activity, which is associated with the activity of the uridine monophosphate (UMP) synthase gene (3q13). These results suggested that the loss of 3q might be a genetic change responsible for the decreased OPRT activity and fluoropyrimidine cytotoxic response in cancer cells. Amplification of 18p11.2-p11.3 containing the thymidine synthase (TS) gene (18p11.32) was observed only in the DLD-1/FdUrd-resistant cell line, which overexpresses TS. These findings suggested that 18p amplification represents a genetic change associated with the overexpression of the TS protein. Our results indicate that chromosomal aberrations identified by CGH could explain, at least in part, acquired fluoropyrimidine resistance.
authors.affiliation: Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Sakamoto Machi, Nagasaki City, Nagasaki 852-8501, Japan. hidaka-s@net.nagasaki-u.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Hidaka
authors.forename: T
authors.initials: T
authors.lastname: Yasutake
authors.forename: M
authors.initials: M
authors.lastname: Fukushima
authors.forename: H
authors.initials: H
authors.lastname: Yano
authors.forename: M
authors.initials: M
authors.lastname: Haseba
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
authors.forename: T
authors.initials: T
authors.lastname: Sawai
authors.forename: H
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: T
authors.initials: T
authors.lastname: Nakagoe
authors.forename: H
authors.initials: H
authors.lastname: Ayabe
authors.forename: Y
authors.initials: Y
authors.lastname: Tagawa
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005468:Fluorodeoxyuridylate / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D009693:Nucleic Acid Hybridization; D014407:Tumor Cells, Cultured
chemical_list: D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D005468:Fluorodeoxyuridylate; D005472:Fluorouracil